Study guide

12.1 Anemia Management: ESAs & Intravenous Iron Therapy

BONENT Certified Hemodialysis Nurse CHN

Track your progress as you read

Finished sections get a check mark.

1 Exam Orientation

1.1 Current CHN Exam Facts and Study Strategy

2 Chapter 1: Renal Anatomy, Physiology & CKD Pathophysiology

2.1 Nephron Physiology & Endocrine Functions 2.2 Acute Kidney Injury & Chronic Kidney Disease Staging 2.3 Fluid, Electrolyte & Acid-Base Imbalances in ESRD

3 Chapter 2: CKD-MBD, Uremia & Clinical Manifestations

3.1 CKD-Mineral and Bone Disorder (CKD-MBD) 3.2 Uremic Syndrome & Multi-System Complications 3.3 Dialysis Patient Education & Nutritional Management

4 Individualized Nursing Care

4.1 Nursing Assessment, Planning and Evaluation 4.2 Treatment Records and Safe Handoffs 4.3 Psychosocial Assessment, Counseling and Referral

5 Chapter 3: Principles of Hemodialysis & Dialysate Chemistry

5.1 Transport Mechanisms: Diffusion, Convection & Ultrafiltration 5.2 Dialyzer Characteristics, Membrane Biocompatibility & Flux 5.3 Dialysate Composition & Concentrate Formulations 5.4 Hemodialysis Adequacy: Urea Kinetics, Kt/V & URR

6 Chapter 4: Vascular Access: Fistulas, Grafts & Catheters

6.1 Arteriovenous Fistulas & Arteriovenous Grafts 6.2 Physical Examination, Surveillance & Monitoring of Access 6.3 Central Venous Catheters & CDC Infection Prevention

7 Chapter 5: Cannulation Practice & Access Complications

7.1 Cannulation Techniques: Rope-Ladder, Buttonhole & Needle Sizing 7.2 Vascular Access Stenosis, Thrombosis & Steal Syndrome 7.3 Access Infiltration, Pseudoaneurysms & Hemorrhage Management

8 Chapter 6: Hemodialysis Treatment Delivery & Circuit Monitoring

8.1 Pre-Dialysis Assessment, Target Dry Weight & UFR Limits 8.2 Extracorporeal Circuit Setup, Priming & Safety Alarms 8.3 Anticoagulation Management: Heparin Protocols & Citrate 8.4 Treatment Termination, Hemostasis & Post-Dialysis Assessment

9 Equipment and Laboratory Skills

9.1 Ancillary Equipment and Bedside Safety 9.2 Blood Sampling, Laboratory Trends and Critical Results

10 Chapter 7: Acute Intradialytic Complications & Emergencies

10.1 Intradialytic Hypotension & Muscle Cramping 10.2 Dialysis Disequilibrium Syndrome & Neurological Events 10.3 Dialyzer Reactions & Hypersensitivity (Type A and Type B) 10.4 Critical Emergencies: Air Embolism, Hemolysis & Blood Loss

11 Extended and Acute Treatment

11.1 Sequential UF, Hemofiltration and Hemoperfusion 11.2 Acute Kidney Injury and High-Risk Dialysis Initiation

12 Chapter 8: Nephrology Pharmacology in Hemodialysis

12.1 Anemia Management: ESAs & Intravenous Iron Therapy 12.2 CKD-MBD Pharmacotherapy: Binders, Vitamin D & Calcimimetics 12.3 Cardiovascular, Antimicrobial & Dialyzable Drug Dosing

13 Home and Peritoneal Dialysis

13.1 Home Dialysis Selection and Adult Learning 13.2 Home Setup, Monitoring and Emergency Readiness 13.3 Peritoneal Dialysis Principles and Nursing Care

14 Kidney Transplantation

14.1 Transplant Benefits, Burdens and Modality Counseling 14.2 Transplant Indications, Contraindications and Referral 14.3 Pretransplant Workup and Waiting-List Coordination 14.4 Immunosuppressants, Interactions and Patient Teaching 14.5 Returning to Dialysis After Graft Failure 14.6 New-Graft Monitoring and Urgent Changes

15 Chapter 9: Water Treatment Systems & Dialyzer Reprocessing

15.1 AAMI/ISO Water Treatment Architecture & Components 15.2 Chemical Contaminant Monitoring & Total Chlorine Testing 15.3 Microbiological Standards, Endotoxin Surveillance & Sampling 15.4 Dialyzer Reprocessing Standards, Testing & Germicide Safety

16 Clinical Unit Management

16.1 Evaluating Dialysis Technology and Supplies 16.2 Staffing, Personnel Policies and Standards of Care

17 Chapter 10: Supervision, Administration & Professional Practice

17.1 RN Delegation, Technician Supervision & Nurse Practice Acts 17.2 CMS Conditions for Coverage & Interdisciplinary Care Planning 17.3 Dialysis Unit Infection Control & Environmental Safety 17.4 Quality Improvement (ESRD QIP), Ethics & Palliative Care

18 Professional Development

18.1 Professional Literature, Organizations and Continuing Learning 18.2 Research Design, Implementation and Evidence Interpretation 18.3 Staff Training, Competency and Remediation

19 Environmental Hazards and Emergency Planning

19.1 Chemical Agents, Disinfection and Exposure Control 19.2 Biological Hazards and Occupational Injury Response 19.3 Fire, Threats and Power or Water Interruptions

12.1 Anemia Management: ESAs & Intravenous Iron Therapy

Key Takeaways Explain This Topic AI

Evaluate iron availability, inflammation and blood loss before escalating ESA therapy.

KDIGO 2026 suggests HD iron initiation with ferritin at most 500 ng/mL and TSAT at most 30%, with routine withholding above ferritin 700 or TSAT at least 40%.

US epoetin labeling directs dose reduction/interruption when dialysis hemoglobin approaches or exceeds 11 g/dL; KDIGO recommends adult ESA targets below 11.5.

Ferumoxytol requires at least a 15-minute infusion and monitoring for at least 30 minutes afterward.

Last updated: October 2026

Anemia Management: ESAs & Intravenous Iron Therapy

Chronic anemia is a common complication of end-stage renal disease ( ESRD ) that profoundly impairs physical function, cognitive performance, and cardiovascular stability. Left untreated, severe renal anemia accelerates left ventricular hypertrophy ( LVH ), congestive heart failure, and mortality in maintenance hemodialysis patients. Modern nephrology nursing requires an in-depth understanding of the hormonal regulation of erythropoiesis, the safe administration of erythropoiesis-stimulating agents ( ESAs ), the biological mechanics of oral hypoxia-inducible factor stabilizers, and the precise titration of intravenous ( IV ) iron.

Pathophysiology of Anemia in CKD and ESRD

The anemia of chronic kidney disease is predominantly normocytic and normochromic, arising from a multifactorial cascade of endocrine, hematologic, and inflammatory defects:

Endogenous Erythropoietin (EPO) Deficiency : Under physiological conditions, specialized peritubular interstitial fibroblasts in the renal cortex synthesize more than 90% of circulating erythropoietin in response to local tissue hypoxia. In progressive CKD, interstitial changes impair the appropriate EPO response to anemia; iron availability, inflammation and blood loss can also contribute. Erythrocyte colony-forming units ( CFU-E ) in the bone marrow undergo premature apoptosis without survival signals from EPO.

Shortened Red Blood Cell Lifespan : Normal erythrocytes circulate for approximately 120 days. In the uremic milieu, red cell survival is reduced to 60 to 90 days (approximately a 25% to 50% reduction in this illustrative range). Uremic guanidines, oxidative stress, and lipid peroxidation stiffen the erythrocyte membrane, inhibit the membrane N a + / K + Na^+/K^+ N a + / K + -ATPase pump, and increase osmotic fragility, driving premature splenic and reticuloendothelial phagocytosis.

Extracorporeal Circuit Blood Trapping & Phlebotomy : Hemodialysis patients experience unavoidable, recurrent blood losses. Dialyzer membrane residual trapping, blood tubing retention, circuit clotting, and routine laboratory draws account for 1 to 3 liters of whole blood loss annually . Repeated losses can deplete iron, but the amount varies with hemoglobin, circuit loss and sampling. A fixed blood-volume loss does not imply one universal annual iron deficit.

Hepcidin Elevation & Reticuloendothelial Iron Blockade : Maintenance hemodialysis is characterized by chronic, low-grade systemic inflammation (elevated interleukin-6 and TNF-alpha). Proinflammatory cytokines stimulate hepatic transcription of hepcidin , the master iron regulatory hormone. Circulating hepcidin binds to, internalizes, and degrades ferroportin , the sole cellular iron export channel on duodenal enterocytes and reticuloendothelial macrophages. Consequently, absorbed dietary iron remains trapped in intestinal enterocytes, and recycled iron remains locked within splenic and hepatic macrophages, creating functional iron deficiency where bone marrow cannot access stored iron.

Erythropoiesis-Stimulating Agents (ESAs)

Recombinant DNA technology provides exogenous erythropoietin analogs to stimulate erythroid proliferation and differentiation:

Epoetin Alfa (Epogen, Procrit) : A recombinant human erythropoietin identical in amino acid sequence to native EPO, possessing three N-linked carbohydrate chains (molecular weight ∼ 30.4 kDa \sim 30.4\text{ kDa} ∼ 30.4 kDa ). It has a short intravenous elimination half-life of 4 to 8 hours in hemodialysis. US labeling gives an adult starting regimen of 50–100 units/kg three times weekly, IV or subcutaneously, with IV recommended in HD. Maintenance and timing follow the actual product and ordered protocol.

Darbepoetin Alfa (Aranesp) : A hyperglycosylated ESA engineered with two additional N-linked carbohydrate chains (five total, molecular weight ∼ 37.1 kDa \sim 37.1\text{ kDa} ∼ 37.1 kDa ). These added carbohydrate chains reduce receptor affinity but dramatically extend the circulating IV half-life to approximately 25 hours (three-fold longer than epoetin alfa). It is administered weekly or every two weeks .

Methoxy Polyethylene Glycol-Epoetin Beta (Mircera / CERA) : A Continuous Erythropoietin Receptor Activator synthesized by conjugating epoetin beta with a linear 30 kDa methoxy polyethylene glycol polymer (molecular weight ∼ 60 kDa \sim 60\text{ kDa} ∼ 60 kDa ). This massive hydrodynamic volume slows receptor association and dissociation, producing an extended elimination half-life of approximately 130 hours IV . It is administered once every two to four weeks .

Clinical Administration & Pure Red Cell Aplasia (PRCA)

In hemodialysis, ESAs are routinely administered intravenously into the venous drip chamber or venous port during rinseback to eliminate painful subcutaneous injections. Rarely, patients develop neutralizing anti-erythropoietin antibodies that cross-react with endogenous EPO and all recombinant ESAs, causing Pure Red Cell Aplasia (PRCA) . PRCA manifests as a sudden drop in hemoglobin of > 1.0 g/dL/week >1.0\text{ g/dL/week} > 1.0 g/dL/week or severe transfusion dependence, with absolute reticulocytopenia ( < 10 , 000 / μ L <10,000/\mu\text{L} < 10 , 000/ μ L ) and absent bone marrow erythroblasts. When PRCA is diagnosed, all ESAs must be discontinued immediately and permanently ; switching to another ESA is contraindicated, and subsequent treatment is specialist-directed.

Hemoglobin Goals and Safety

KDIGO 2026 generally favors ESA initiation around hemoglobin 9–10 g/dL in dialysis and recommends an adult ESA maintenance target below 11.5 g/dL, individualized to symptoms and transfusion risk. This does not create a universal 10–11.5 target for every patient. US epoetin labeling directs use of the lowest dose sufficient to reduce transfusions and reduction or interruption if hemoglobin approaches or exceeds 11 g/dL in dialysis. A US nurse follows the actual ordered protocol and applicable product labeling rather than treating KDIGO’s upper limit as permission to continue unchanged at 11.4.

ESAs carry boxed warnings for death, cardiovascular events, thrombosis and other risks. Monitor blood pressure, hemoglobin trend, dose response and access thrombosis risk. Correct iron deficiency and assess inflammation, bleeding or other causes before escalating for hyporesponsiveness. An abrupt hemoglobin fall requires evaluation rather than automatic dose doubling. Uncontrolled hypertension is a contraindication to epoetin treatment. Sudden severe anemia with reticulocytopenia may require evaluation for pure red-cell aplasia; the specialist determines testing and subsequent treatment.

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs)

HIF-PHIs (such as daprodustat and vadadustat ) represent an oral class of agents for dialysis-dependent CKD anemia. In normoxic states, prolyl hydroxylase domain (PHD) enzymes hydroxylate proline residues on hypoxia-inducible factor alpha ( H I F − 1 α HIF-1\alpha H I F − 1 α and H I F − 2 α HIF-2\alpha H I F − 2 α ). Hydroxylated HIF-alpha is recognized by the von Hippel-Lindau (VHL) protein, which directs it to the proteasome for degradation.

HIF-PHIs reversibly inhibit PHD enzymes, preventing HIF-alpha degradation. Stabilized HIF-alpha translocates into the nucleus, dimerizes with HIF-beta, and activates hypoxia response elements on target genes. This triggers a coordinated physiologic response:

Stimulates endogenous EPO transcription in cortical peritubular fibroblasts and hepatocytes.

Suppresses hepatic hepcidin synthesis , unlocking reticuloendothelial iron stores.

Upregulates duodenal iron transport proteins ( DCYTB , DMT1 , and ferroportin ), significantly enhancing intestinal iron absorption.

Intravenous Iron Therapy & Monitoring

Effective erythropoiesis requires adequate bioavailable iron. Blood loss and inflammation-related iron restriction often make oral replacement insufficient in HD. KDIGO 2026 favors IV over oral iron when initiating therapy in HD, with review of infection and the overall clinical situation. Intravenous (IV) iron therapy is the clinical standard of care.

Iron Biomarkers and KDIGO 2026

TSAT estimates circulating iron availability, whereas ferritin reflects stores and can rise with inflammation. KDIGO 2026 suggests initiating iron in anemia with HD when ferritin is at most 500 ng/mL and TSAT at most 30%. Withhold routine iron when ferritin is above 700 ng/mL or TSAT at least 40%; consider suspending iron during active systemic infection. Interpret trends, blood loss, response and the ordered protocol rather than diagnosing overload from ferritin alone.

IV Iron Formulations Comparison

Formulation Composition Typical Dosing in HD Nursing & Administration Precautions

Iron Sucrose (Venofer) Polynuclear iron(III)-hydroxide in sucrose 100 mg 100\text{ mg} 100 mg IV push over 2–5 min or in 100 mL 100\text{ mL} 100 mL saline over 15 min No test dose required; give early in HD as labeled; monitor for hypersensitivity and hypotension.

Sodium Ferric Gluconate (Ferrlecit) Macromolecular iron gluconate complex 125 mg 125\text{ mg} 125 mg IV diluted in 100 mL 100\text{ mL} 100 mL saline over 60 min No test dose required; monitor for hypersensitivity and hypotension.

Ferumoxytol Iron oxide complex Labeled infusion of at least 15 minutes Observe during and for at least 30 minutes after infusion; monitor BP/pulse and hypersensitivity.

Iron dextran (INFeD) Low-molecular-weight iron dextran Dose and administration follow the current label Boxed anaphylaxis warning; required test dose and monitoring do not eliminate reaction risk.

All IV iron products require readiness to recognize and treat hypersensitivity. Observe for at least the labeled period and until stable after administration; no test-dose exemption eliminates serious reaction risk.

Sources checked 2026-10-10: KDIGO 2026 anemia , epoetin label , ferumoxytol label

Product sources checked 2026-10-11: Venofer label , Ferrlecit label .